Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: a rebuttal |
| |
| Authors: | J. P. PATEL B. GREEN R. K. PATEL J. G. DAVIES R. ARYA |
| |
| Affiliation: | 1. King’s Thrombosis Centre, Department of Haematology, King’s College Hospital Foundation NHS Trust, Denmark Hill, London;2. Institute of Pharmaceutical Science, King’s College London, London, UK;3. Model Answers Pty Ltd, Brisbane, Qld, Australia |
| |
| Abstract: | See also Liesenfled K‐H, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, EzekowitzMD, Yusuf S,Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial. J Thromb Haemost 2011; 9: 2168–75; and Liesenfeld K‐H, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with on‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal. This issue, pp 502–4. |
| |
| Keywords: | |
|
|
